



10th GUILDFORD ADVANCED PAIN & SYMPTOM MANAGEMENT COURSES **5-6th September 2022, London** **26-27th September 2022, Manchester**

Reading List

New opioid analgesics - Dr Andrew Dickman

- Varga BR et al. Strategies towards safer opioid analgesics-A review of old and upcoming targets. *Br J Pharmacol.* 2021 Nov 26;10.1111/bph.15760 Epub ahead of print
- Wiffen PJ et al. Oral tapentadol for cancer pain. *Cochrane Database of Systematic Reviews* 2015, Issue 9. Art. No.: CD011460 [reviewed Sept 2020].
- Überall MA et al. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry. *Pain Manag.* 2022; 12(2):211-227.
- Ziemichod W et al. Cebranopadol as a Novel Promising Agent for the Treatment of Pain. *Molecules.* 2022 Jun 21;27(13):3987
- Christoph A et al. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. *Pain.* 2017 Sep;158(9):1813-1824
- Eerdeken MH, et al. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. *Eur J Pain.* 2019 Mar;23(3):577-588.
- Viscusi ER. A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain. *Expert Rev Neurother.* 2022 Jun;22(6):419-426.
- Somogyi AA et al. New pharmacological perspectives and therapeutic options for opioids: Differences matter. *Anaesth Intensive Care.* 2022 Mar;50(1-2):127-140.
- Dahan A et al. Respiratory effects of the nociceptin/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers. *Anesthesiology.* 2017; 126:697–707
- Viscusi ER et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the μ -opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. *J Pain Res.* 2019; 12:927-943.
- Singla NK et al. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ -Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty. *Pain Pract.* 2019; 19(7):715-731

Opioids for non-pain indications – Ms Jo Thompson

- Abdallah S et al. Effect of morphine on breathlessness and exercise endurance in advanced COPD: a randomised crossover trial. *Eur Respir J.* 2017; 50: 2-13

- Adballah S et al. Updates in opioid and nonopioid treatment for chronic breathlessness. *Curr Opin Support Palliat Care*. 2019; 13:167-173
- Abdallah S et al. Opioids for breathlessness: psychological and neural factors influencing response variability. *Eur Respir J*. 2019; 54: 1-5
- Afolabi T et al. Nebulized opioids for the palliation of dyspnea in terminally ill patients. *Am J Health-Syst Pharm*. 2017; 74(14); 1053-1061
- Currow D et al. Opioids for chronic refractory breathlessness: Right patient, right route? *Drugs*. 2014; 74: 1-6
- Currow D et al. A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. *BMJ Open*. 2017; 7: 1-18
- Ferreira D et al. Patients' and their caregivers' experiences with regular, low-dose, sustained-release morphine for chronic breathlessness associated with COPD: a qualitative study. *BMJ Open Resp Res*. 2022; 9: 1-11
- Johnson M et al. Oral modified release morphine for breathlessness in chronic heart failure: a randomised placebo-controlled trial. *ESC Heart Failure*. 2019; 6:1149-1160
- Johnson M & Currow D. Opioids for breathlessness: a narrative review. *BMJ Supportive & Palliative Care*. 2020; 10: 287-295
- Ning L et al. Efficacy and safety of opioids in treating cancer-related dyspnoea: A systematic review and meta-analysis based on randomised controlled trials. *Journal of Pain and Symptom Management*. 2020; 61(1): 198-210
- van Dijk M et al. Opioids in patients with COPD and refractory dyspnoea: literature review and design of a multicentre double blind study of low dose morphine and fentanyl (MoreFoRCOPD). *BMC Pulm Med*. 2021; 21(289)
- Verberkt C et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status. A randomized controlled trial. *JAMA Intern Med*. 2020; 180(10): 1306-1314
- Al-Sheklly B et al. Randomised controlled trial quantifying the efficacy of low dose morphine in a responder group of patients with refractory chronic cough. *Thorax*. 2017; 72(Suppl – 3): A24
- Dion G et al. Treatment of neurogenic cough with tramadol: A pilot study. *Otolaryngology – Head and Neck Surgery*. 2017; 157(1)77-79
- Homsy J et al. Important drugs for cough in advanced cancer. *Support Care Cancer*. 2001 ; 9 : 565-574
- Molassiotis A et al. Interventions for cough in cancer. *Cochrane Database of Systematic Reviews* 2015, Issue 5. Art. No.: CD007881. DOI: 10.1002/14651858.CD007881.pub3.
- Molassiotis A et al. Symptomatic treatment of cough among adult patients with lung cancer. *Chest*. 2017; 151(4): 861-874
- Visca D et al. Management of chronic refractory cough in adults. *European Journal of Internal Medicine*. 2020; 81: 1-7
- Woo-Jung S & Chung K. Pharmacotherapeutic options for chronic refractory cough. *Expert Opinion on Pharmacotherapy*. 2020; 21(11) 1345-1358
- Yancy S et al. Efficacy and tolerability of treatment for chronic cough. A Systematic review and Meta-analysis. *Chest*. 2013; 144(6): 1827-1838
- Bossi P et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. *Annals of Oncology*. 2018; 29(supplement 4) 126-142
- Davis H. <https://www.sps.nhs.uk/articles/high-dose-loperamide-use-in-high-stoma-output-or-short-bowel-syndrome/> 2022; (accessed 1st July 2022)

- Komurcu S et al. Gastrointestinal symptoms among inpatients with advanced cancer. *Am J Hospice and Palliative Care*. 2002; 19(5): 351-355
- Nightingale J et al. Guidelines for management of patients with a short bowel. *Gut*. 2006; 55 (supplement iv)
- Schiller L. Antidiarrhoeal drug therapy. *Current Gastroenterol Rep*. 2017; 19(18)
- Brown R et al. Opioids for agitation in dementia. *Cochrane Database of Systematic Reviews* 2015, Issue 5. Art. No.: CD009705.
- Rawal H & Patel B. Opioids in Cardiovascular disease: therapeutic options. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2018; 23(4): 279-291
- Silber M et al. The Management of restless legs syndrome: An updated algorithm. *Mayo Clin Proc*. 2021; 96(7): 1921-1937
- Trenkwalder C et al. prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double blind, randomised, placebo-controlled trial with an open label extension. *Lancet Neurology*. 2013; 12: 1141-50
- Zhang D et al. The safety of morphine in patients with acute heart failure: A systematic review and meta-analysis. *Clin Cardiol*. 2021; 44:1216-1224

What else is new (pain)? – Prof Andrew Davies / Dr Andrew Dickman

- Faculty of Pain Medicine website: <https://fpm.ac.uk/opioids-aware/opioids-and-addiction>
- Hindmarch T, Dalrymple J, Smith M, Barclay S. Spiritual interventions for cancer pain: a systematic review and narrative synthesis. *BMJ Support Palliat Care* 2022;12(1):1-9.
- Merlin JS, Khodyakov D, Arnold R et al. Expert Panel Consensus on management of advanced cancer-related pain in individuals with opioid use disorder. *JAMA Netw Open*. 2021;4(12):e2139968.
Open access: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787463>
- Schmidt-Hansen M, Bennett MI et al. Oxycodone for cancer-related pain. *Cochrane Database Syst Rev* 2022;6(6):CD003870.
Open access: https://www.cochrane.org/CD003870/SYMPT_oxycodone-cancer-related-pain-adults
- Silva Carvalho F, Carvalho S, Conde R, Esteves S. Cynotherapy in cancer pain management: a pilot study. *Pain Med* 2021;22(12):3051-61.
- Sine H, Achbani A, Filali K. The effect of hypnosis on the intensity of pain and anxiety in cancer patients: a systematic review of controlled experimental trials. *Cancer Invest* 2022;40(3):235-53.
- Wilcock A, Howard P, Charlesworth S. *Palliative Care Formulary*, 7th edition. London: Pharmaceutical Press; 2020.
- Kopsky DJ, et al. Topical loperamide for the treatment of localized neuropathic pain: a case report and literature review. *J Pain Res*. 2019; 12:1189-1192
- Jyothi B et al. Morphine Versus Loperamide with Intrasite Gel in the Treatment of Painful Dermal Ulcers: A Randomized, Crossover Study. *Pain Physician*. 2021 Jan;24(1):E37-E44
- Brown DC et al. Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain. *Pain*. 2015 Jun;156(6):1018-1024

Gabapentinoids – wolves in sheep’s clothing? – Prof Andrew Davies

- Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. *Pain* 2001;92(1-2):147-57.
- Caraceni A, Zecca E, Bonezzi C et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. *J Clin Oncol* 2004;22(14):2909-17.
- Derry S, Bell RF, Straube S, Wiffen PJ et al. Pregabalin for neuropathic pain in adults. *Cochrane Database Syst Rev* 2019;1(1):CD007076.
Open access: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007076.pub3/full>
- El Najjar MR, El Hariri M, Ramadan A et al. A double blind, placebo controlled, randomized trial to evaluate the efficacy and tolerability of on-demand oral pregabalin (150 mg and 75 mg) in treatment of premature ejaculation. *J Sex Med* 2020;17(3):442-446.
- Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. *Drugs* 2017;77(4):403-426.
- Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015;14(2):162-73.
Open access: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493167/>
- Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. *JAMA Intern Med* 2019;179(5):695-701.
- Green K, Cooke O'Dowd N, Watt H et al. Prescribing trends of gabapentin, pregabalin, and oxycodone: a secondary analysis of primary care prescribing patterns in England. *BJGP Open*. 2019 Oct 29;3(3):bjgpopen19X101662.
Open access: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970586/>
- Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. *Curr Opin Support Palliat Care* 2018;12(2):108-117.
- Kane CM, Mulvey MR, Wright S et al. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: systematic review and meta-analysis. *Palliat Med*. 2018;32(1):276-286.
- Lyndon A, Audrey S, Wells C et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. *Addiction*. 2017 Sep;112(9):1580-1589.
Open access: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635829/>
- Mathieson S, Lin CC, Underwood M et al. Pregabalin and gabapentin for pain. *BMJ* 2020;369:m1315.
- MHRA Drug Safety Alert (2017):
<https://www.gov.uk/drug-safety-update/gabapentin-neurontin-risk-of-severe-respiratory-depression>
- MHRA Drug Safety Alert (2019):
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/795950/April-2019-PDF-final.pdf
- Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. *JAMA* 2018;320(20):2149-2151.
Open access: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583557/>
- PHE Advice (2014):
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/385791/PHE-NHS_England_pregabalin_and_gabapentin_advice_Dec_2014.pdf

- Rasmussen PV, Sindrup SH, Jensen TS et al. Symptoms and signs in patients with suspected neuropathic pain. *Pain* 2004;110(1-2):461-9.
- Vedula SS, Bero L, Scherer RW et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. *N Engl J Med* 2009;361(20):1963-71.
- Open access: https://www.nejm.org/doi/10.1056/NEJMsa0906126?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov

Safe opioid usage – Dr Cathy Stannard

- Campbell G, Nielsen S, Bruno R et al. The Pain and Opioids IN Treatment study; characteristics of a cohort using opioids to manage chronic non-cancer pain *Pain* 2015;156(2):231-42
- GMC 2021. Good practice in prescribing and managing medical devices https://www.gmc-uk.org/-/media/documents/prescribing-guidance-updated-english-20210405_pdf-85260533.pdf
- Macfarlane G, Beasley M, Jones G and Stannard C. The epidemiology of regular opioid use and its association with mortality: Prospective cohort study of 466 486 UK biobank participants *EClinicalMedicine* 2020 Apr; 21: 100321
- Miller M, Barber C, Leatherman S et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy *JAMA Intern Med*. doi:10.1001/jamainternmed.2014.8071
- NICE guideline [NG193]. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain Published: 07 April 2021 <https://www.nice.org.uk/guidance/ng193>
- NICE guideline [NG215]. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults Published: 20 April 2022 <https://www.nice.org.uk/guidance/ng215>
- NICE guideline [NG59]. Low back pain and sciatica in over 16s: assessment and management Published: 30 November 2016 Last updated: 11 December 2020 <https://www.nice.org.uk/guidance/NG59>
- Udayachalerm S, Bair MJ, Illingworth P et al. Opioid prescribing and health outcomes in opioid-naïve patients: analysis of a statewide health information exchange. *JAPhA* 2021; DOI: 10.1016/j.japh.2021.04.020
- Von Korff M, Merrill J, Rutter C et al. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy *Pain* 152 (2011) 1256–1262
- Zhang Y, Johnson P, Jeng PJ et al First opioid prescription and subsequent high-risk opioid use: A national study of privately insured and Medicare advantage adults. *J Gen Intern Med* 2018; 33(12):2156-2162

Oral care in advanced disease – Prof Andrew Davies

- Cleary N, Munnely Mulkerrin O, Davies A. Oral symptom assessment tools in patients with advanced cancer: a scoping review. *Supportive Care in Cancer*; 2022. Open access: <https://link.springer.com/article/10.1007/s00520-022-07169-1>
- Davies A. Oral care. In: Cherny N, Fallon M, Kaasa S, Portenoy RK, Currow DC, editors. *Oxford Textbook of Palliative Medicine*, 6th Edition. Oxford: Oxford University Press; 2021.
- Davies AN, Epstein JB. *Oral Complications of Cancer and its Management*. Oxford: Oxford University Press; 2010.

- Davies A, Finlay I. Oral Care in Advanced Disease. Oxford: Oxford University Press; 2005.
- Jones JA, Chavarri-Guerra Y, Corrêa LB et al. MASCC / ISOO expert opinion on the management of oral problems in patients with advanced cancer. Supportive Care in Cancer; 2022.
Open access: <https://link.springer.com/article/10.1007/s00520-022-07211-2>
- Oral Health Foundation. White paper on optimal care and maintenance of full dentures for oral and general health (2018): <https://www.dentalhealth.org/denturecareguidelines>
- Sweeney P (2005) Oral hygiene. Davies A, Finlay I (eds) Oral care in advanced disease. Oxford University Press, Oxford, pp 21-35.

Nausea & vomiting – what, when and why? – Dr Paul Paes

- Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A (2000) A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. *J Pain Symptom Manag* 19(6):427–435
- Bruera ED, MacEachern TJ, Spachynski KA et al (1994) Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. *Cancer* 74(12):3204–3211
- Bruera E, Moyano JR, Sala R et al (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. *J Pain Symptom Manag* 28(4):381–388
- Corli O, Cozzolino A, Battaiotto L (1995) Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. *J Pain Symptom Manag* 10(7):521–526
- Cox L, Darvill E, Dorman S. Levomepromazine for nausea and vomiting in palliative care. *Cochrane Database Syst Rev*. 2015 Nov 2;2015(11):CD009420
<https://www.crediblemeds.org/>
- Davis MP, Hallerberg G (2010) Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. *J Pain Symptom Manag* 39(4):756–767
- Davis, M, Hui, D, Davies, A et al. (2021) MASCC antiemetics in advanced cancer updated guideline. *Support Care Cancer* 29, 8097–8107
- Davis, M., Hui, D., Davies, A. et al. (2021) Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. *Support Care Cancer* 29, 8089–8096
- Hardy J, Skerman H, Glare P, Philip J, Hudson P, Mitchell G, Martin P, Spruyt O, Currow D, Yates P (2018) A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. *BMC Cancer* May 2;18(1):510 18(1):510
- Hardy JR, Skerman H, Philip J, Good P, Currow DC, Mitchell G, Yates P (2019) Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea: a randomised, double-blind controlled trial. *BMJ Open* 9(9):e029942
- Hardy JR, O’Shea A, White C, Gilshenan K, Welch L, Douglas C (2010) The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. *J Pain Symptom Manag* 40(1):111–116
- Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E (2021). Fixed-dose netupitant and

- palonosetron for chronic nausea in cancer patients: a double-blind, placebo run-in pilot randomized clinical trial. *J Pain Symptom Manag* 62:223–232.e1
- Mystakidou K, Befon S, Trifyllis J, Lioffi C, Papadimitriou J (1997) Tropisetron versus metoclopramide in the control of emesis in far-advanced cancer. *Oncologist* 2(5):319–323
 - Mystakidou K, Befon S, Lioffi C, Vlachos L (1998) Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. *Cancer* 83(6):1214–1223
 - Murray-Brown F, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. *Cochrane Database Syst Rev*. 2015 Nov 2;2015(11):CD006271
 - Navari, R.M. (2020) Nausea and Vomiting in Advanced Cancer. *Curr. Treat. Options in Oncol.* 21, 14
 - Navari RM, Pywell CM, Le-Rademacher JG et al (2020). Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial. *JAMA Oncol* 6(6):895–899
 - Palliative Care Formulary:
<https://www.medicinescomplete.com/#/content/palliative/anti-emetics>
 - Rummel-Kluge C, Komossa K, Schwarz S, et al. (2012). Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. *Schizophrenia Bulletin*. Jan;38(1):167-177
 - Sande TA, Laird BJA, Fallon MT (2019) The management of opioid-induced nausea and vomiting in patients with cancer: a systematic review. *J Palliat Med* 22(1):90–97
 - Saudemont G, Prod'Homme C, Da Silva A, Villet S, Reich M, Penel N, Gamblin V. The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. *BMC Palliat Care*. 2020 Apr 22;19(1):56
 - Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. *Cochrane Database Syst Rev*. 2018 Sep 21;9(9):CD012555
 - Walsh D, Davis M, Ripamonti C et al.(2017) 2016 Updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. *Support Care Cancer* 25(1):333–340

Octreotide – what is it good for? – Dr Andrew Dickman

- Lamberts SW et al. Octreotide. *N Engl J Med*. 1996 Jan 25;334(4):246-54.
- Günther T et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. *Pharmacol Rev*. 2018 Oct;70(4):763-835.
- Currow DC et al. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. *J Pain Symptom Manage*. 2015 May;49(5):814-21.
- Obita GP et al. Somatostatin Analogues Compared With Placebo and Other Pharmacologic Agents in the Management of Symptoms of Inoperable Malignant Bowel Obstruction: A Systematic Review. *J Pain Symptom Manage*. 2016 Dec;52(6):901-919.e1.
- Davis M, et al. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. *Support Care Cancer*. 2021 Dec;29(12):8089-8096
- Madariaga A et al. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer. *Support Care Cancer*. 2022 Jun;30(6):4711-4728.

- Bossi P et al. ESMO Guidelines Committee. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2018 Oct;29 Suppl 4:iv126-iv142.

What else is new (symptoms)? – Prof Andrew Davies / Dr Andre Dickman

- Innominato PF, Spiegel D, Ulusakarya A et al. Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. *Sleep Med* 2015; 16(3):391-8.
- Lévi F, Dugué PA, Innominato P et al. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. *Chronobiol Int* 2014;31(8):891-900.
Access from: https://www.researchgate.net/profile/Arti-Parganiha/publication/316060915_Wrist_actimetry_circadian_rhythm_as_a_robust_predictor_of_colorectal_cancer_patients_survival/links/58ee74b70f7e9b37ed16c09e/Wrist-actimetry-circadian-rhythm-as-a-robust-predictor-of-colorectal-cancer-patients-survival.pdf
- Stone PC, Kalpakidou A, Todd C et al. The Prognosis in Palliative care Study II (PiPS2): A prospective observational validation study of a prognostic tool with an embedded qualitative evaluation. *PLoS One*. 2021 Apr 28;16(4):e0249297.
- Open access:
<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249297>
- Wernli U et al. Subcutaneous Drugs and Off-label Use in Hospice and Palliative Care: A Scoping Review. *J Pain Symptom Manage*. 2022 Jul 20:S0885-3924(22)00824-7. Epub ahead of print
- Agar M et al. The use of subcutaneous omeprazole in the treatment of dyspepsia in palliative care patients. *J Pain Symptom Manage*. 2004;28:529-531.
- Desmidt T et al. Subcutaneous infusion of esomeprazole in elderly patients in palliative care: a report of two cases. *J Am Geriatr Soc*. 2009;57(9):1724-1725
- Michelon H et al. Subcutaneous pantoprazole in an elderly, palliative care patient. *BMJ Support Palliat Care*. 2019;1-2.
- Hindmarsh J et al. Administering esomeprazole subcutaneously via a syringe driver in the palliative demographic: A case series. *J Clin Pharm Ther*. 2022 May;47(5):694-698.
- Leheup BF et al. Subcutaneous administration of paracetamol-Good local tolerability in palliative care patients: An observational study. *Palliat Med*. 2018 Jul;32(7):1216-1221
- El Khoury J et al. Evaluation of efficacy and safety of subcutaneous acetaminophen in geriatrics and palliative care (APAPSUBQ). *BMC Palliat Care*. 2022; 21(1):42